Aurobindo Pharma Ltd vs Piramal Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1382 as of 04 May 10:42 . The P/E Ratio of Aurobindo Pharma Ltd changed from 9.7 on March 2021 to 19.3 on March 2025 . This represents a CAGR of 14.75% over 5 yearsThe P/E Ratio of Piramal Pharma Ltd changed from 991.5 on March 2024 to 325.4 on March 2025 . This represents a CAGR of -42.71% over 2 years The Market Cap of Aurobindo Pharma Ltd changed from ₹ 51653 crore on March 2021 to ₹ 67951 crore on March 2025 . This represents a CAGR of 5.64% over 5 yearsThe Market Cap of Piramal Pharma Ltd changed from ₹ 8165 crore on March 2023 to ₹ 29763 crore on March 2025 . This represents a CAGR of 53.90% over 3 years The revenue of Aurobindo Pharma Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 8833 crore. This represent the decline of -100% The revenue of Piramal Pharma Ltd for the Mar '26 is ₹ 2811 crore as compare to the Dec '25 revenue of ₹ 2193 crore. This represent the growth of 28.18% The ebitda of Aurobindo Pharma Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 1896 crore. This represent the decline of -100% The ebitda of Piramal Pharma Ltd for the Mar '26 is ₹ 344.37 crore as compare to the Dec '25 ebitda of ₹ 208.12 crore. This represent the growth of 65.47% The net profit of Aurobindo Pharma Ltd changed from ₹ 918.22 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Piramal Pharma Ltd changed from ₹ -88.64 crore to ₹ -8.83 crore over 8 quarters. This represents a CAGR of -68.44% The Dividend Payout of Aurobindo Pharma Ltd changed from 7.53 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Piramal Pharma Ltd changed from 18.07 % on March 2022 to 2.68 % on March 2025 . This represents a CAGR of -37.94% over 4 years .

About Aurobindo Pharma Ltd

Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in December 1986 as a private limited company.
Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
APL is running with 29 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

About Piramal Pharma Ltd

Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

FAQs for the comparison of Aurobindo Pharma Ltd and Piramal Pharma Ltd

Which company has a larger market capitalization, Aurobindo Pharma Ltd or Piramal Pharma Ltd?

Market cap of Aurobindo Pharma Ltd is 80,705 Cr while Market cap of Piramal Pharma Ltd is 21,520 Cr

What are the key factors driving the stock performance of Aurobindo Pharma Ltd and Piramal Pharma Ltd?

The stock performance of Aurobindo Pharma Ltd and Piramal Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aurobindo Pharma Ltd and Piramal Pharma Ltd?

As of May 4, 2026, the Aurobindo Pharma Ltd stock price is INR ₹1389.55. On the other hand, Piramal Pharma Ltd stock price is INR ₹161.9.

How do dividend payouts of Aurobindo Pharma Ltd and Piramal Pharma Ltd compare?

To compare the dividend payouts of Aurobindo Pharma Ltd and Piramal Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.